ASND
NASDAQAscendis Pharma A/S
News · 26 weeks67-57%
2026-04-192026-10-11
Mix3190d
- Other12(39%)
- SEC Filings10(32%)
- Insider4(13%)
- Analyst3(10%)
- Earnings2(6%)
Latest news
25 items- SECSEC Form 6-K filed by Ascendis Pharma A/S6-K - Ascendis Pharma A/S (0001612042) (Filer)
- PROnce-Weekly TransCon® CNP (Navepegritide) Receives Positive CHMP Opinion for the Treatment of Achondroplasia in ChildrenCOPENHAGEN, Denmark, Oct. 16, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending marketing authorization for once-weekly TransCon CNP (navepegritide) in the European Union for the treatment of achondroplasia in children two years of age and older whose epiphyses are not closed. The final European Commission (EC) decision on Ascendis Pharma’s Marketing Authorisation Application (MAA) is expected during Q4 2026. "We are pleased to receive this positive opinion reflecting the unique profile of TransCon CNP," said Jan Mikkels
- SECSEC Form 6-K filed by Ascendis Pharma A/S6-K - Ascendis Pharma A/S (0001612042) (Filer)
- PRAscendis to Share Latest Advances in Hypoparathyroidism and Achondroplasia Programs at ASBMR 2026COPENHAGEN, Denmark, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced that the latest advances in its hypoparathyroidism and achondroplasia programs will be showcased during ASBMR 2026, the annual meeting of American Society for Bone & Mineral Research being held in Boston from October 9-12, 2026. Updates include an oral presentation by Aliya Khan, M.D., of combined skeletal data from the Phase 2 PaTH Forward and Phase 3 PaTHway trials showing normalization of bone mass and microarchitecture in clinical trial patients treated with TransCon® PTH (palopegteriparatide) over a 5-year period. "Our growing body of clinical trial data continues to illustrate th
- SECSEC Form 6-K filed by Ascendis Pharma A/S6-K - Ascendis Pharma A/S (0001612042) (Filer)
- INSIDERSEC Form 4 filed by Director Bienaime Jean Jacques4 - Ascendis Pharma A/S (0001612042) (Issuer)
- ANALYSTAscendis Pharma downgraded by Raymond James with a new price targetRaymond James downgraded Ascendis Pharma from Strong Buy to Outperform and set a new price target of $287.00
- PRAscendis Announces Planned $400 Million Share Repurchase ProgramCOPENHAGEN, Denmark, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced that its Board of Directors has authorized the Company to repurchase up to $400 million of the Company’s ordinary shares (the Share Repurchase Program). Purchases under the planned Share Repurchase Program may be made from time to time, in such amounts as management deems appropriate, through a variety of methods, which may include open market purchases, privately negotiated transactions, block trades, accelerated share repurchase transactions, purchases through 10b5-1 trading plans, or by any combination of such methods. The timing and amount of any repurchases pursuant to the Share
- PRAscendis to Regain Rights to TransCon® Technology in Metabolic and Cardiovascular Diseases- All rights to TransCon technology-based products in metabolic and cardiovascular diseases, including once-monthly TransCon Semaglutide, will revert to Ascendis- Ascendis to initiate multiple programs in metabolic and cardiovascular diseases, including obesity COPENHAGEN, Denmark, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced that it will regain the exclusive rights to develop, manufacture, and commercialize TransCon technology-based products in metabolic and cardiovascular diseases, including obesity. This follows termination of the collaboration agreement between Ascendis and Novo Nordisk A/S announced in November 2024. Under the terms of the agre
- SECSEC Form 6-K filed by Ascendis Pharma A/S6-K - Ascendis Pharma A/S (0001612042) (Filer)
- INSIDERSVP & PAO Bodenhoff Mads exercised 3,000 units of Ordinary Shares at a strike of $110.00 and sold $810,570 worth of Ordinary Shares (3,000 units at $270.19) (SEC Form 4)4 - Ascendis Pharma A/S (0001612042) (Issuer)
- SECSEC Form 6-K filed by Ascendis Pharma A/S6-K - Ascendis Pharma A/S (0001612042) (Filer)
- PRFirst Infant Data from Ascendis Trial of Once-Weekly TransCon CNP (Navepegritide) Presented at ESPE 2026– Achondroplasia Foramen Magnum Score was stable or improved between baseline and Week 52 with TransCon CNP treatment – Treatment with TransCon CNP increased linear growth in the sentinel cohort, with an improvement in ACH-specific supine length Z-score of +0.42 from baseline through Week 52 – Treatment with TransCon CNP was generally well tolerated, with no reports of injection site reactions over the 52-week treatment period COPENHAGEN, Denmark, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced Week 52 data from the open-label sentinel cohort portion of the reACHin Trial (which preceded the now fully enrolled double-blinded portion of the trial) sho
- PRAscendis Pharma to Participate in the Morgan Stanley 24th Annual Global Healthcare ConferenceCOPENHAGEN, Denmark, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced that company executives will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on Tuesday, September 15, 2026, at 8:30 a.m. Eastern Time / 5:30 a.m. Pacific Time in New York, New York. A live webcast of the presentation will be available via the Investors & News section of the Ascendis Pharma website at investors.ascendispharma.com. A webcast replay will also be available on this website shortly after conclusion of the event for 30 days. About Ascendis Pharma A/SAscendis Pharma is a global biopharmaceutical company focused on applying our i
- PRAscendis to Share Its Latest Endocrinology Rare Disease Data at ESPE 2026COPENHAGEN, Denmark, Sept. 07, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced it will share the latest data from its Endocrinology Rare Disease programs during ESPE 2026, the annual congress of the European Society for Paediatric Endocrinology (ESPE) being held September 8-10, 2026, in Marseille, France. Updates will include a podium presentation of the first sentinel cohort data from the pivotal reACHin Trial of TransCon CNP (navepegritide) in infants with achondroplasia aged 0 to <2 years. "Ascendis is building leadership with its growing portfolio of treatments for people living with hypoparathyroidism and growth disorders, which we look forward to showcasin
- INSIDERDirector Holtug Lars sold $62,335 worth of Ordinary Shares (236 units at $264.13), decreasing direct ownership by 6% to 4,000 units (SEC Form 4)4 - Ascendis Pharma A/S (0001612042) (Issuer)
- SECSEC Form 6-K filed by Ascendis Pharma A/S6-K - Ascendis Pharma A/S (0001612042) (Filer)
- PRAscendis and BioMarin Enter Binding Term Sheet for a Global Settlement and License Agreement Related to YUVIWEL® (Navepegritide)COPENHAGEN, Denmark, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced it has entered into a binding term sheet for a global settlement and license agreement with BioMarin Pharmaceutical Inc. ("BioMarin") related to the sale of YUVIWEL® and navepegritide-related products. The binding term sheet provides the terms and conditions upon which the companies agree to resolve all litigation and disputes between the companies. Under the terms, BioMarin has agreed to grant Ascendis a non-exclusive, worldwide, royalty-bearing license, allowing Ascendis to continue researching, developing, manufacturing, and commercializing navepegritide-related products without res
- ANALYSTH.C. Wainwright initiated coverage on Ascendis Pharma with a new price targetH.C. Wainwright initiated coverage of Ascendis Pharma with a rating of Buy and set a new price target of $345.00
- PRAscendis Announces Oral Presentation of Week 104 Data from Its Pivotal Trial of TransCon® CNP (Navepegritide) at ISDS 2026COPENHAGEN, Denmark, Aug. 25, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced that its participation at ISDS 2026, the annual meeting of the International Skeletal Dysplasia Society being held in Toronto, Canada, from August 26-29, 2026, will include an oral presentation of Week 104 data from its pivotal ApproaCH Trial of once-weekly TransCon CNP (navepegritide) in children with achondroplasia. The presentation will be given by Carlos Bacino, M.D., FACMG, Professor of Molecular and Human Genetics, Baylor College of Medicine and Texas Children’s Hospital. "This long-term data reinforces the benefits seen in clinical trials of once-weekly TransCon CNP, which hav
- ANALYSTBMO Capital Markets initiated coverage on Ascendis Pharma with a new price targetBMO Capital Markets initiated coverage of Ascendis Pharma with a rating of Outperform and set a new price target of $319.00
- INSIDERDirector Bienaime Jean Jacques bought $492,654 worth of Ordinary Shares (2,000 units at $246.33), increasing direct ownership by 222% to 2,900 units (SEC Form 4)4 - Ascendis Pharma A/S (0001612042) (Issuer)
- PREyconis Announces Initiation of First-in-Human Clinical Trial of EYC-0305 in Treatment-Naïve Wet Age-Related Macular Degeneration PatientsFirst patients dosed in OVERTURE, a Phase 1b/2a study evaluating EYC-0305, a potential long-acting anti-VEGF therapy designed for six-month or longer dosing intervals via standard intravitreal injection Milestone marks Eyconis’ transition to a clinical-stage biotechnology company REDWOOD CITY, Calif., Aug. 18, 2026 (GLOBE NEWSWIRE) -- Eyconis, Inc., a biotechnology company developing next-generation, long-acting ophthalmic therapeutics, today announced the initiation of OVERTURE, the company’s first-in-human Phase 1b/2a clinical trial of EYC-0305 in treatment-naïve patients with neovascular, or wet, age-related macular degeneration (AMD). The first patients have been dosed in the study,
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Ascendis Pharma A/SSCHEDULE 13G/A - Ascendis Pharma A/S (0001612042) (Subject)
- SECSEC Form 6-K filed by Ascendis Pharma A/S6-K - Ascendis Pharma A/S (0001612042) (Filer)
ASND FAQ
7 questionsWhat does Ascendis Pharma A/S do?
Ascendis Pharma A/S, a biopharmaceutical company, develops therapeutics for unmet medical needs. The company develops TransCon growth hormone, which completed Phase III clinical trials for growth hormone deficiency. It also develops TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for achondroplasia. In addition, the company develops preclinical studies in the field of oncology for potential product candidates and evaluate systemic and localized delivery systems using its TransCon technologies. The company was incorporated in 2006 and is headquartered in Hellerup...Where does ASND stock trade?
Ascendis Pharma A/S (ASND) is listed on NASDAQ.What sector and industry is ASND in?
Ascendis Pharma A/S operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Ascendis Pharma A/S go public?
Ascendis Pharma A/S (ASND) completed its IPO in 2015.What are analysts saying about ASND?
Ascendis Pharma A/S has had 8 recent analyst actions on file. The most recent action was from Raymond James: Outperform on 2026-09-15.What companies are similar to ASND?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare ASND side-by-side with any of them on Quantisnow.How can I track ASND on Quantisnow?
Quantisnow aggregates Ascendis Pharma A/S's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ASND to receive live email and push alerts on every new disclosure.